Literature DB >> 29128051

The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Christina C Lindenmeyer1, Arthur J McCullough2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease worldwide, and its clinical and economic burden will continue to grow with parallel increases in rates of obesity, diabetes, and the metabolic syndrome. Evolving understanding of the natural history of NAFLD suggests that these patients are at risk for disease progression to steatohepatitis, fibrosis, and cirrhosis. Recent studies also suggest that these patients are at elevated risk for cardiovascular-, malignancy-, and liver-related morbidity and mortality, although their risk for progression, decompensation, and hepatocellular carcinoma may be less than that of patients with alternative causes of chronic liver disease. Published by Elsevier Inc.

Entities:  

Keywords:  Cirrhosis; Fibrosis; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Steatosis

Mesh:

Year:  2018        PMID: 29128051      PMCID: PMC6130315          DOI: 10.1016/j.cld.2017.08.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  72 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Amedeo Lonardo
Journal:  Adv Ther       Date:  2016-02-26       Impact factor: 3.845

3.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

4.  Recurrence of nonalcoholic steatohepatitis following liver transplantation.

Authors:  W R Kim; J J Poterucha; M K Porayko; E R Dickson; J L Steers; R H Wiesner
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

Review 8.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.

Authors:  Zobair M Younossi; Linda Henry
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

9.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  60 in total

1.  Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.

Authors:  Luan Nguyen; Maryam Masouminia; Alejandro Mendoza; Sara Samadzadeh; Brittany Tillman; Timothy Morgan; Barbara French; Samuel French
Journal:  Exp Mol Pathol       Date:  2018-01-04       Impact factor: 3.362

Review 2.  Adipose Tissue Composition in Obesity and After Bariatric Surgery.

Authors:  Gian Franco Adami; Federico Carbone; Fabrizio Montecucco; Giovanni Camerini; Renzo Cordera
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

Review 3.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

4.  Synergism of Adipocytokine Profile and ADIPOQ/TNF-α Polymorphisms in NAFLD-associated MetS Predict Colorectal Liver Metastases Outgrowth.

Authors:  Rosa Divella; Antonella Daniele; Raffaele DE Luca; Antonio Mazzocca; Eustachio Ruggieri; Eufemia Savino; Porzia Casamassima; Michele Simone; Carlo Sabba; Angelo Paradiso
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

5.  Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).

Authors:  Yue Jia; Barbara French; Brittany Tillman; Samuel French
Journal:  Exp Mol Pathol       Date:  2018-07-17       Impact factor: 3.362

Review 6.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022

Review 7.  Current treatment paradigms and emerging therapies for NAFLD/NASH.

Authors:  Sana Raza; Sangam Rajak; Aditya Upadhyay; Archana Tewari; Rohit Anthony Sinha
Journal:  Front Biosci (Landmark Ed)       Date:  2021-01-01

Review 8.  From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.

Authors:  Peng Zhao; Alan R Saltiel
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

9.  Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.

Authors:  He-Ming Huang; Shi-Jie Fan; Xiao-Ru Zhou; Yan-Jun Liu; Xiao Li; Li-Ping Liao; Jing Huang; Cui-Cui Shi; Liang Yu; Rong Fu; Jian-Gao Fan; Yuan-Yuan Zhang; Cheng Luo; Guang-Ming Li
Journal:  Acta Pharmacol Sin       Date:  2021-08-02       Impact factor: 6.150

10.  Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.

Authors:  P León-Mimila; H Villamil-Ramírez; X S Li; D M Shih; S T Hui; E Ocampo-Medina; B López-Contreras; S Morán-Ramos; M Olivares-Arevalo; P Grandini-Rosales; L Macías-Kauffer; I González-González; R Hernández-Pando; F Gómez-Pérez; F Campos-Pérez; C Aguilar-Salinas; E Larrieta-Carrasco; T Villarreal-Molina; Z Wang; A J Lusis; S L Hazen; A Huertas-Vazquez; S Canizales-Quinteros
Journal:  Diabetes Metab       Date:  2020-08-10       Impact factor: 6.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.